Compass Therapeutics, INC 8-K filings

Compass Therapeutics announced its second quarter 2026 financial results, detailing progress in its oncology drug pipeline and maintaining a cash runway into 2028.

Compass Therapeutics presented updated corporate information, including data from its COMPANION-002 clinical study for tovecimig, highlighting significant improvements in key endpoints.

Compass Therapeutics, Inc. announced the final voting results from its Annual Meeting of Stockholders held on June 10, 2026, including the election of directors and ratification of its independent auditor.

Compass Therapeutics reported Q1 2026 financial results, highlighting positive Phase 2/3 data for tovecimig in biliary tract cancer and updates on other pipeline candidates.

Compass Therapeutics announced positive Phase 2/3 data for tovecimig in combination with paclitaxel for biliary tract cancer, meeting key PFS endpoint and showing significant ORR.

Compass Therapeutics announced its 2025 financial results, highlighting significant pipeline progress including key clinical trial milestones and a strong cash position extending into 2028.

Compass Therapeutics provided a corporate update, highlighting pipeline progress, strong cash position, and key leadership appointments.

Compass Therapeutics reported third quarter 2025 financial results and provided key updates on its clinical pipeline, including delayed data readouts for tovecimig and CTX-8371, and a strong cash position.

Compass Therapeutics, a clinical-stage oncology company, announced the pricing of an upsized $120 million public offering of common stock and pre-funded warrants to fund clinical development and commercial readiness.

Compass Therapeutics announced its second quarter 2025 financial results and provided updates on its clinical pipeline, including promising data for CTX-8371 and a delay in tovecimig's overall survival data due to fewer patient deaths.

Compass Therapeutics, Inc. announced the successful election of three Class II director nominees and the ratification of CohnReznick, LLP as its independent registered public accounting firm at its Annual Meeting of Stockholders held on June 11, 2025.

Compass Therapeutics reports positive topline results for Tovecimig in biliary tract cancer, advances its pipeline, and maintains a strong cash position.

Compass Therapeutics announces that tovecimig, in combination with paclitaxel, met its primary endpoint in a Phase 2/3 study for patients with biliary tract cancer (BTC), demonstrating a statistically significant improvement in overall response rate (ORR) compared to paclitaxel alone.

Compass Therapeutics reports its 2024 financial results, highlighting a strong cash position and progress in its clinical pipeline, with key data readouts and trial initiations expected in 2025.

Compass Therapeutics announced the advancement of a new drug candidate, CTX-10726, and provided an update on its clinical programs and financial position.

Compass Therapeutics has appointed Barry Shin as its new Chief Financial Officer and Neil Lerner as Principal Accounting Officer, effective December 9, 2024.

Compass Therapeutics reported its third quarter 2024 financial results, highlighted clinical trial progress, and provided updates on its pipeline, including a cash runway into the first quarter of 2027.

Compass Therapeutics reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a key clinical trial and provided updates on its various drug development programs.

Compass Therapeutics held its annual meeting on June 13, 2024, electing two directors and ratifying its independent accounting firm.

Compass Therapeutics has announced the resignation of Vered Bisker-Leib as CEO and the appointment of Thomas Schuetz as the new CEO, effective May 28, 2024.

Compass Therapeutics reported its first quarter 2024 financial results, highlighted by a $10.8 million net loss and progress in its clinical programs, including FDA Fast Track designation for CTX-009.

Compass Therapeutics has been granted Fast Track Designation by the FDA for its bispecific antibody, CTX-009, in combination with paclitaxel, for the treatment of advanced biliary tract cancer.

Compass Therapeutics announced its 2023 financial results, highlighted clinical trial progress, and provided a corporate update, including a cash runway into mid-2026.